Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC vs IV Cisplatin at Interval Cytoreductive Surgery for Stage III/IV Ovarian Cancer
NCT05415709Phase 1Active, not recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Cisplatin micelle injection (HA132) in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Incidence of chemotherapy-related adverse events at 30 days. Started Jun 2022; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05415709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415709.